A Phase 1, Open-label, Non-randomized, Dose-escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination With CPT-11 and Bevacizumab in Patients With Advanced Gastrointestinal Tumors

Trial Profile

A Phase 1, Open-label, Non-randomized, Dose-escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination With CPT-11 and Bevacizumab in Patients With Advanced Gastrointestinal Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Irinotecan
  • Indications Gastrointestinal cancer
  • Focus Adverse reactions
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 12 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
    • 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 25 Apr 2016 Planned number of patients changed from 78 to 65.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top